View clinical trials related to CS1+ or BCMA+ Multiple Myeloma.
Filter by:This is a single-center, open-label, single-arm study to evaluate the safety and efficacy of the bispecific CAR T cells targeting CS1 and BCMA in patients with relapsed or refractory multiple myeloma.